Project 2

项目2

基本信息

  • 批准号:
    8434770
  • 负责人:
  • 金额:
    $ 12.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-03-05 至 2015-02-28
  • 项目状态:
    已结题

项目摘要

Human papillomavirus (HPV) infection is the most common viral sexually transmitted infection (STI), and infection with high-risk types of HPV has been implicated in the majority of anogenital malignancies. Worldwide, HPV-related cervical cancer is the second most common cause of malignancy in women. Over the past 40 years in the United States, cervical cancer incidence rates have been dramatically reduced, which is believed to be the result of Pap smear screening. Incidence rates are distinctly increased in minority, underserved populations. In the United States, African American women have 30% higher incidence of cervical cancer and a 2-fold increased risk of mortality as compared to Caucasian women. These findings are more striking in Louisiana, where African American women have almost a 50% increase in incidence and a 3-fold increase in mortality over their Caucasian counterparts. Even in the African-American population, where HPV infection rates are high, relatively few women progress to cervical abnormalities. This fact indicates that HPV infection is necessary but not sufficient for the development of cervical cancer. Thus, other cofactors must augment the oncogenic potential of HPV. The known oncogenic virus, Epstein-Barr virus (EBV), is shed from the cervix, making this a prime co-factor candidate for HPV-related cervical dysplasia. Preliminary data strongly suggest that EBV may be a co-factor to HPV in the pathogenesis of cervical dysplasia, irrespective of HIV status. It is hypothesized that HIV-negative women who shed both EBV and high-risk HPV from their cervix are at greater risk for cervical dysplasia than women who shed only high-risk HPV. From this hypothesis, it is predicted that (1) the rate of cervical dysplasia will be increased in those women co-shedding both EBV and HPV; (2) EBV and HPV cervical shedding will be detected prior to the development of cervical dysplasia; (3) EBV and HPV will be located in the same cervical epithelial cells or in close proximity; (4) analysis of co-infected cervical tissue will demonstrate loss of cell cycle control pathways and inhibition of apoptosis pathways; and (5) prophylactic HPV vaccination will prevent these events.
人乳头瘤病毒(HPV)感染是最常见的病毒性性传播感染(STI),并且大多数肛门生殖器恶性肿瘤涉及高危型HPV感染。在世界范围内,HPV相关的宫颈癌是女性恶性肿瘤的第二大常见原因。在过去的40年里,美国的宫颈癌发病率大幅下降,这被认为是巴氏涂片筛查的结果。发病率明显增加, 少数民族,服务不足的人群。在美国,非裔美国妇女的宫颈癌发病率比白人妇女高30%,死亡风险增加2倍。这些发现在路易斯安那州更引人注目,非洲裔美国妇女的发病率几乎增加了50%,死亡率比白人妇女增加了3倍。即使在HPV感染率很高的非洲裔美国人中,也有相对较少的妇女进展到宫颈癌。 异常这一事实表明,HPV感染是必要的,但不足以发展宫颈癌。因此,其他辅因子必须增加HPV的致癌潜力。已知的致癌病毒Epstein-Barr病毒(EBV)从宫颈脱落,使其成为HPV相关宫颈发育不良的主要辅助因子候选者。初步数据强烈提示,EBV可能是HPV在宫颈发育不良发病机制中的辅助因子,而与HIV状态无关。据推测,艾滋病毒阴性 从子宫颈同时排出EBV和高危HPV的妇女比仅排出高危HPV的妇女发生子宫颈不典型增生的风险更大。根据这一假设,可以预测:(1)在那些同时脱落EBV和HPV的妇女中,宫颈不典型增生的发生率将增加;(2)在宫颈不典型增生发生之前,将检测到EBV和HPV宫颈脱落;(3)EBV和HPV将位于相同的宫颈上皮细胞中或非常接近;(4)对共感染的宫颈组织的分析将有助于发现HPV和EBV的共同脱落。 证明细胞周期控制途径的丧失和细胞凋亡途径的抑制;和(5)预防性HPV疫苗接种将预防这些事件。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BETTY P. DENNIS其他文献

BETTY P. DENNIS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BETTY P. DENNIS', 18)}}的其他基金

Project 3
项目3
  • 批准号:
    8434771
  • 财政年份:
    2013
  • 资助金额:
    $ 12.19万
  • 项目类别:
Impact of Man-made Disasters on the Underserved: Lesson Learned from BP Oil Spill
人为灾难对服务不足的人群的影响:英国石油公司漏油事件的教训
  • 批准号:
    8129967
  • 财政年份:
    2011
  • 资助金额:
    $ 12.19万
  • 项目类别:
Project 1
项目1
  • 批准号:
    8102545
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:
Community Core
社区核心
  • 批准号:
    8102543
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:
Training Core
培训核心
  • 批准号:
    8102541
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:
Dillard-LSUHSC Minority Health and Health Disparities Research Center
迪拉德-路易斯安那州立大学HSC 少数族裔健康与健康差异研究中心
  • 批准号:
    7880307
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:
Project 2
项目2
  • 批准号:
    8102547
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:
ADMIN CORE
管理核心
  • 批准号:
    8102538
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:
Research Core
研究核心
  • 批准号:
    8102540
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:
Project 3
项目3
  • 批准号:
    8102550
  • 财政年份:
    2010
  • 资助金额:
    $ 12.19万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 12.19万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 12.19万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 12.19万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.19万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 12.19万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 12.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 12.19万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 12.19万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 12.19万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 12.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了